Entera Bio Ltd. Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing covers the month of March 2021 for Entera Bio Ltd., a foreign private issuer headquartered in Jerusalem, Israel. The report details the results of an Extraordinary General Meeting of Shareholders held on March 3, 2021.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance matters and does not contain financial statements or operational metrics.
Material Changes
There are no material financial changes reported in this document. The primary event is the shareholder approval of executive compensation terms.
Management Commentary and Corporate Actions
- Shareholder Resolution: Shareholders duly approved the ratification and approval of the terms of compensation for Dr. Spiros Jamas, the Company's Chief Executive Officer and director.
- Effective Date: The approved compensation terms commence as of January 4, 2021, and continue onward.
- Legal Basis: The approval was conducted in accordance with the majority requirements under the Israeli Companies Law 5759-1999 and the Company's Articles of Association.
Key Facts for Investor Verification
- Verify the specific compensation terms for Dr. Spiros Jamas in the Proxy Statement filed on January 11, 2021 (Exhibit 99.1 referenced in this filing).
- Confirm the voting percentages and quorum details from the March 3, 2021 meeting minutes if not fully detailed in the referenced Proxy Statement.
- Note that this filing contains no financial performance data for the period.